NasdaqGS:IBRXBiotechs
Did ANKTIVA’s Expanding Approvals and Chemo‑Free GBM Data Just Shift ImmunityBio’s (IBRX) Investment Narrative?
In January 2026, ImmunityBio reported expanded enrollment in its Phase 2 QUILT-3.078 glioblastoma trial, updated FDA interactions on a supplemental Biologics License Application for ANKTIVA in papillary non-muscle invasive bladder cancer, and secured Saudi approval for ANKTIVA in bladder cancer carcinoma in situ.
Together with very large recent sales growth for ANKTIVA and emerging data on a chemotherapy-free regimen in glioblastoma, these regulatory and clinical steps underscore how...